The physiological differences between solid tumours and the healthy tissues and organs of the body are both an impediment to effective treatment and a potential basis for targeting strategies. In the present review, we outline the physiological features that distinguish tumours including hypoxia, acidity, and inhibited transport and describe the strategies being employed to exploit these differences in order to generate more selective and less toxic anticancer agents.